Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain

Cancer Letters

Volumn 358, Issue 2, 2015, Pages 93-99

  Patil, Ajay ^a   Sherbet, G V ^b  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Brain metastases; Breast cancer; HER2; Signalling pathways

Indexed keywords

BUPARLISIB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RITUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIATION NECROSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SKULL IRRADIATION; STEM CELL GENE THERAPY; SYSTEMIC THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; BREAST TUMOR; DISEASE MANAGEMENT; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; NEURAL STEM CELL; PATHOLOGY; RADIOTHERAPY; SECONDARY; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE MANAGEMENT; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEURAL STEM CELLS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOTHERAPY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84921608611     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.026     Document Type: Review

References (62)

1. Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer. J. Clin. Oncol 2004, 17:3608-3617.
2. Nam B.H., Kim S.Y., Han H.S., Kwon Y., Lee K.S., Kim T.H., et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10:R20.
3. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am. J. Surg. Pathol 2006, 30:1097-1104.
4. Miller K.D., Weathers T., Haney L.G., Timmerman R., Dickler M., Shen J., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Annals Oncol 2003, 14:1072-1077.
5. Sherbet G.V. Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy 2011, Elsevier.
6. Klapper L.N., Kirschbaum M.H., Sela M., Yarden Y. Biochemical and clinical implications of ErbB/HR signaling network of growth factor receptors. Adv. Cancer Res 2000, 77:25-79.
7. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol 1999, 17:2639-2648.
8. Shepard H.M., Jin P., Slamon D.J., Pirot Z., Maneval D.C. Herceptin, handbook. Exp. Pharmacol 2008, 181:183-219.
9. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol 2002, 20:719-726.
10. Gonzalez-Angulo A.M., Akcakanat A., Liu S., Green M.C., Murray J.L., Chen H., et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Annals Oncol 2014, 25:1122-1127.
11. Tovey S.M., Brown S., Doughty J.C., Mallon E.A., Cooke T.G., Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br. J. Cancer 2009, 100:680-683.
12. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res 2003, 284:99-110.
13. Singh J.C., Jhaveri K., Esteva F.J. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br. J. Cancer 2014, 111:1888-1898.
14. Komen S.G. Breast cancer subtypes http://ww5.komen.org/BreastCancer/SubtypesofBreastCancer.html.
15. Minisini A.M., Moroso S., Gerratana L., Giangreco M., Iacono D., Poletto E., et al. Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin. Exp. Metastasis 2013, 30:951-956.
16. Aversa C., Rossi V., Geuna E., Martinello R., Milani A., Redana S., et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014, 23:623-628.
17. Berghoff A.S., Bartsch R., Preusser M., Ricken G., Steger G.G., Bago-Horvath Z., et al. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast 2014, 23:637-843.
18. Kumar S., Taylor G. Specific lymphotoxicity and blocking factors in tumour of the central nervous system. Br. J. Cancer 1973, 28(Suppl. I):135-141.
19. Gu Y.T., Xue Y.X., Wang Y.F., Wang J.H., ShangGuan Q.R., Zhang J.X., et al. Role of ROS/RhoA/PI3K/PKB signaling in NS1619-mediated blood-tumor barrier permeability increase. J. Mol. Neurosci 2012, 48:302-312.
20. Swain S.M., Baselga J., Miles D., Im Y.H., Quah C., Lee L.F., et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann. Oncol 2014, 25:1116-1121.
21. Yap Y.S., Cornelio G.H., Devi B.C.R., Khorprasert C., Kim S.B., Kim T.Y., et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br. J. Cancer 2012, 107:1075-1082.
22. Renfrow J.J., Lesser G.J. Molecular subtyping of brain metastases and implications for therapy. Curr. Treat. Op. Oncol 2013, 14:514-527.
23. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18:23-28.
24. Lin N.U., Winer E.P. Brain metastases: the HER2 paradigm. Clin. Cancer Res 2007, 13:1648-1655.
25. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int. J. Cancer 1991, 49:650-655.
26. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals Oncol 2006, 17:935-944. International Breast Cancer Study Group (IBCSG).
27. Arjaans M., Munnink T.H.O., Oosting S.F., van Scheltinga A.G.T.T., Gietema J.A., Garbacik E.T., et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013, 73:3347-3355.
28. Loebbecke M., Fuchs I., Evers K. Efficacy of Herceptin treatment on brain metastasis in women with HER2 overexpressing breast cancer [abstract 521]. Breast Cancer Res. Treat 2001, 69:302.
29. Yonemori K., Tsuta K., Shimizu C., Hatanaka Y., Hashizume K., Ono M., et al. Immunohistochemical profiles of brain metastases from breast cancer. J. Neurooncol 2008, 90:223-228.
30. Pectasides D., Gaglia A., Arapantoni-Dadioti P., Bobota A., Valavanis C., Kostopoulou V., et al. HER2 status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006, 26:647-653.
31. Ruzevick J., Kleinberg L., Rigamonti D. Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice. Neurosurg. Rev 2014, 37:193-201.
32. dos Santos Zimmer A., Cameron D. Challenges of brain metastasis in ErbB2 (HER2-positive) breast cancer and the potential of small molecule. Eur. Oncological Dis 2007, 1:14-18.
33. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl Cancer Inst 2008, 100:1092-1103.
34. Colozza M., Minenza E., Gori S., Fenocchio D., Paolucci C., Aristei C., et al. Extended survival of a HER2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother. Pharmacol 2009, 63:1157-1159.
35. Grossi P.M., Ochiai H., Archer G.E., McLendon R.E., Zalutsky M.R., Friedman A.H., et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin. Cancer Res 2003, 9:5514-5522.
36. Perissinotti A.J., Reeves D.J. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann. Pharmacother 2010, 44:1633-1640.
37. Gabos Z., Sinha R., Hanson J., Chauhan N., Hugh J., Mackey J.R., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J. Clin. Oncol 2006, 24:5658-5663.
38. Buyukhatipoglu H., Sevinc A., Pehlivan Y., Camci C. Is prophylactic cranial irradiation a possible option for human epidermal growth factor receptor 2-positive breast cancer?. J. Clin. Oncol 2007, 25:1292.
39. Hohensee I., Lamszus K., Riethdorf S., Meyer-Staeckling S., Glatzel M., Matschke J., et al. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am. J. Pathol 2013, 183:83-95.
40. Bachmann C., Grischke E.M., Fehm T., Staebler A., Schittenhelm J., Wallwiener D. CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. J. Cancer Res. Clin. Oncol 2013, 139:551-556.
41. Sherbet G.V. Genetic Recombination in Cancer 2003, Academic/Elsevier, London.
42. Longva K.E., Pedersen N.M., Haslekås C., Stang E., Madshus I.H. Herceptin induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 2005, 116:359-367.
43. Yamazaki M., Yamashita Y., Kubo N., Yashiro M., Ohira M., Ako E., et al. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Oncol. Rep 2012, 28:49-54.
44. D'Alessio A., De Luca A., Maiello M.R., Lamura L., Rachiglio A.M., Napolitano M., et al. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res. Treat 2010, 123:387-396.
45. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., et al. Suppression of HER2/HER3-,ediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res 2009, 15:4147-4156.
46. Saura C., Bendell J., Jerusalem G., Su S., Ru Q.H., De Buck S., et al. Phase Ib study of Buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin. Cancer Res 2014, 20:1935-1945.
47. Sherbet G.V. Therapeutic Strategies in Cancer Biology and Pathology 2013, Elsevier.
48. Biswas D.K., Cruz A.P., Gansberger E., Pardee A.B. Epidermal growth factor induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8542-8547.
49. Pianetti S., Arsura M., Romieu-Mourez R., Coffey R.J., Sonenshein G.E. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001, 20:1287-1299.
50. Fan S., Gao M., Meng Q., Laterra J.J., Symons M.H., Coniglio S. Role of NF-kappa B signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005, 24:1749-1766.
51. Kim J.H., Gupta S.C., Park B., Yadv V.R., Aggarwal B.B. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol. Nutr. Food Res 2012, 56:454-465.
52. Chen C.C., Sureshbabul M., Chen H.W., Lin Y.S., Lee J.Y., Hong Q.S., et al. Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer. Evid. Based Complement. Alternat. Med 2013, 10.1155/2013/541695.
53. 421 Cortactin is over expressed in colon cancer and is dephosphorylated by curcumin: involvement of non-receptor type 1 protein tyrosine phosphatase (PTPN1). PLoS ONE 2014, 9:e85796.
54. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G., et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br. J. Cancer 2008, 98:923-930.
55. Normanno N., Campiglio M., De L.A., Somenzi M., Maiello M., Ciardiello F., et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol 2002, 13:65-72.
56. Menon L.G., Shi V.J., Carroll R.S. Mesenchymal Stromal Cells as a Drug Delivery System 2009, The Stem Cell Research Community, StemBook. 10.3824/stembook.1.35.1. StemBook (Ed.).
57. Wang C., Natsume A., Lee H.J., Motomura K., Nishimira Y., et al. Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. Cancer Gene Ther 2012, 19:796-801.
58. Frank R.T., Edmiston M., Kendall S.E., Najbauer J., Cheunr C.W., Kassa T., et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS ONE 2009, 4.
59. Liu L., Eckert M.A., Riazifar H., Kang D.K., Agalliu D., Zhao W. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier?. Stem Cells Int 2013, Article No. 435093.
60. Díaz-Coránguez M., Segovia J., López-Ornelas A., Puerta-Guardo H., Ludert J., Chavez B., et al. Transmigration of neural stem cells across the blood brain barrier induced by glioma cells. PLoS ONE 2013, 8.
61. erbB2. Science 1992, 256:1205-1210.
62. Badescu A., Georgescu C.V., Vere C.C., Craitoiu S., Grigore D. Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. Rom. J. Morphol. Embryol 2012, 53:997-1005.